Logo image of COCH

ENVOY MEDICAL INC (COCH) Stock Fundamental Analysis

NASDAQ:COCH - Nasdaq - US29415V1098 - Common Stock - Currency: USD

1.48  -0.04 (-2.89%)

Fundamental Rating

1

Taking everything into account, COCH scores 1 out of 10 in our fundamental rating. COCH was compared to 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of COCH have multiple concerns. COCH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

COCH had negative earnings in the past year.
In the past year COCH has reported a negative cash flow from operations.
COCH Yearly Net Income VS EBIT VS OCF VS FCFCOCH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 0 10M -10M -20M

1.2 Ratios

The Return On Assets of COCH (-267.83%) is worse than 96.28% of its industry peers.
Industry RankSector Rank
ROA -267.83%
ROE N/A
ROIC N/A
ROA(3y)-129.02%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COCH Yearly ROA, ROE, ROICCOCH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 1K -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for COCH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COCH Yearly Profit, Operating, Gross MarginsCOCH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

COCH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for COCH has been reduced compared to 1 year ago.
COCH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COCH Yearly Shares OutstandingCOCH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M 40M 50M
COCH Yearly Total Debt VS Total AssetsCOCH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -48.41, we must say that COCH is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -48.41, COCH is not doing good in the industry: 91.49% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -48.41
ROIC/WACCN/A
WACC8.94%
COCH Yearly LT Debt VS Equity VS FCFCOCH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

COCH has a Current Ratio of 0.79. This is a bad value and indicates that COCH is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.79, COCH is doing worse than 92.02% of the companies in the same industry.
A Quick Ratio of 0.61 indicates that COCH may have some problems paying its short term obligations.
The Quick ratio of COCH (0.61) is worse than 92.02% of its industry peers.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.61
COCH Yearly Current Assets VS Current LiabilitesCOCH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2M 4M 6M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for COCH have decreased strongly by -3355.96% in the last year.
Looking at the last year, COCH shows a very strong growth in Revenue. The Revenue has grown by 247.50%.
EPS 1Y (TTM)-3355.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-368.48%
Revenue 1Y (TTM)247.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-30%

3.2 Future

Based on estimates for the next years, COCH will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.45% on average per year.
COCH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 28.92% yearly.
EPS Next Y24.25%
EPS Next 2Y12.5%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue Next Year-6.81%
Revenue Next 2Y5.64%
Revenue Next 3Y28.92%
Revenue Next 5YN/A

3.3 Evolution

COCH Yearly Revenue VS EstimatesCOCH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 200K 400K 600K
COCH Yearly EPS VS EstimatesCOCH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

COCH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for COCH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COCH Price Earnings VS Forward Price EarningsCOCH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COCH Per share dataCOCH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as COCH's earnings are expected to grow with 18.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.5%
EPS Next 3Y18.45%

More info and screens

0

5. Dividend

5.1 Amount

COCH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENVOY MEDICAL INC

NASDAQ:COCH (2/21/2025, 8:10:29 PM)

1.48

-0.04 (-2.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-14 2024-11-14/bmo
Earnings (Next)N/A N/A
Inst Owners3.92%
Inst Owner Change70.82%
Ins Owners54.1%
Ins Owner Change-58.46%
Market Cap31.51M
Analysts82
Price Target7.14 (382.43%)
Short Float %1.18%
Short Ratio2.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.77%
Min EPS beat(2)-32.71%
Max EPS beat(2)-4.83%
EPS beat(4)0
Avg EPS beat(4)-38.57%
Min EPS beat(4)-96.08%
Max EPS beat(4)-4.83%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-26.65%
Min Revenue beat(2)-34.11%
Max Revenue beat(2)-19.19%
Revenue beat(4)1
Avg Revenue beat(4)-22.26%
Min Revenue beat(4)-42.16%
Max Revenue beat(4)6.44%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.67%
PT rev (3m)17.89%
EPS NQ rev (1m)-1.04%
EPS NQ rev (3m)-15.47%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.74%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 113.34
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.35
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-1.26
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0.01
BVpS-0.87
TBVpS-0.87
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -267.83%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-129.02%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 887.28%
Cap/Sales 552.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.61
Altman-Z -48.41
F-Score1
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-3355.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-368.48%
EPS Next Y24.25%
EPS Next 2Y12.5%
EPS Next 3Y18.45%
EPS Next 5YN/A
Revenue 1Y (TTM)247.5%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-30%
Revenue Next Year-6.81%
Revenue Next 2Y5.64%
Revenue Next 3Y28.92%
Revenue Next 5YN/A
EBIT growth 1Y-188.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-80.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-896.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-839.37%
OCF growth 3YN/A
OCF growth 5YN/A